"Hydroxychloroquine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
| Descriptor ID |
D006886
|
| MeSH Number(s) |
D03.633.100.810.050.180.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydroxychloroquine".
Below are MeSH descriptors whose meaning is more specific than "Hydroxychloroquine".
This graph shows the total number of publications written about "Hydroxychloroquine" by people in this website by year, and whether "Hydroxychloroquine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2017 | 7 | 6 | 13 |
| 2018 | 7 | 8 | 15 |
| 2019 | 2 | 5 | 7 |
| 2020 | 274 | 233 | 507 |
| 2021 | 89 | 77 | 166 |
| 2022 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Hydroxychloroquine" by people in Profiles.
-
Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. Eur Respir J. 2022 01; 59(1).
-
Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. Eur Respir J. 2022 01; 59(1).
-
QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine. J Cardiovasc Med (Hagerstown). 2022 01 01; 23(1):e21-e23.
-
Retrospective evaluation of seven different treatment protocols in hospitalized COVID-19 patients Turk J Med Sci. 2021 12 13; 51(6):2835-2849.
-
Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19 Turk J Med Sci. 2021 12 13; 51(6):2827-2834.
-
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. Am J Epidemiol. 2021 11 02; 190(11):2405-2419.
-
Ongoing Citations of a Retracted Study Involving Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19. JAMA Intern Med. 2021 11 01; 181(11):1535-1537.
-
Arrhythmogenesis and COVID-19. Cardiol Rev. 2021 Nov-Dec 01; 29(6):289-291.
-
How trustworthy guidelines can impact outcomes. Curr Opin Crit Care. 2021 10 01; 27(5):544-550.
-
COVID-19: potential therapeutics for pediatric patients. Pharmacol Rep. 2021 Dec; 73(6):1520-1538.